Obesity Pillars, Journal Year: 2025, Volume and Issue: unknown, P. 100175 - 100175
Published: April 1, 2025
Language: Английский
Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: 20(5), P. 261 - 277
Published: Feb. 6, 2024
Language: Английский
Citations
53
Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(3), P. 454 - 499
Published: Jan. 30, 2024
Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.
Language: Английский
Citations
31
Military Medical Research, Journal Year: 2024, Volume and Issue: 11(1)
Published: May 29, 2024
Abstract Mitochondria, the most crucial energy-generating organelles in eukaryotic cells, play a pivotal role regulating energy metabolism. However, their significance extends beyond this, as they are also indispensable vital life processes such cell proliferation, differentiation, immune responses, and redox balance. In response to various physiological signals or external stimuli, sophisticated mitochondrial quality control (MQC) mechanism has evolved, encompassing key like biogenesis, dynamics, mitophagy, which have garnered increasing attention from researchers unveil specific molecular mechanisms. this review, we present comprehensive summary of primary mechanisms functions regulators involved major components MQC. Furthermore, critical regulated by MQC its diverse roles progression systemic diseases been described detail. We discuss agonists antagonists targeting MQC, aiming explore potential therapeutic research prospects enhancing stabilize function.
Language: Английский
Citations
30
Nutrients, Journal Year: 2025, Volume and Issue: 17(1), P. 178 - 178
Published: Jan. 2, 2025
The connections between sarcopenia and various chronic conditions, including type 2 diabetes (T2DM), metabolic syndrome (MetS), liver disease have been highlighted recently. There is also a high occurrence of in dysfunction-associated steatotic (MASLD) patients, who are often disregarded. Both experimental clinical findings suggest complex, bidirectional relationship MASLD sarcopenia. While vitamin D, testosterone, specific drug therapies show promise mitigating sarcopenia, consensus on effective treatments lacking. Recent focus lifestyle interventions emphasizes dietary therapy exercise for sarcopenic obesity MASLD. Challenges arise as weight loss, primary treatment, may lead to muscle mass reduction. therapeutic approach morbidly obese patients includes bariatric surgery (BS). BS induces loss stabilizes imbalances, but its impact nuanced, underscoring the need further research. Our aim provide comprehensive review interplay offer insight into most recent challenges discoveries, overlooked or unrecognized poses significant managing these patients.
Language: Английский
Citations
2
Metabolism, Journal Year: 2023, Volume and Issue: 147, P. 155676 - 155676
Published: Aug. 4, 2023
Language: Английский
Citations
34
Current Obesity Reports, Journal Year: 2024, Volume and Issue: 13(3), P. 532 - 544
Published: May 16, 2024
Sarcopenic obesity (SO), defined as the coexistence of excess fat mass and reduced skeletal muscle strength, has emerged an important cardiovascular risk factor, particularly in older adults. This review summarizes recent findings on diagnosis, prevalence, health impacts, treatment SO.
Language: Английский
Citations
13
Clinical Nutrition, Journal Year: 2025, Volume and Issue: 47, P. 282 - 290
Published: March 4, 2025
Language: Английский
Citations
1
Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 156113 - 156113
Published: Dec. 1, 2024
Language: Английский
Citations
8
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(10), P. 2880 - 2880
Published: May 13, 2024
Background: Sarcopenic obesity (SO) is the combination of excess fat, skeletal muscle and muscular strength/function deficit. The ESPEN/EASO have proposed new diagnostic criteria, but SO prevalence in patients with severe remains to be established. aim this study was establish a large cohort inpatients obesity, considering sex, age, BMI, type, number concomitant diseases. Methods: Patient data both genders aged between 18 90 years body mass index (BMI) ≥30 kg/m2 underwent hospital evaluation including bioelectrical impedance analysis (BIA) handgrip strength (HS). QoL scores were obtained by Psychological General Well-Being Index questionnaire. approved institutional Ethic Committee. Results: Among 3858 patients, 444 (11.51%) exhibited deficit, while 3847 (99.71%) had then 11.48%, higher rates women (12.39%), individuals >70 (27%), those reporting ‘poor’ (12.6%). No significant difference found when stratifying BMI (30–40 vs. >40 kg/m2, p = 0.1710). In osteoarticular diseases (57%), hypertension/heart failure (38%), type 2 diabetes mellitus (34%), obstructive sleep apnea (32%) more frequent comorbidities. Conclusions: application ESPEN/EASO-SO criteria revealed 11.48% prevalence, which associated age (particularly > 70 years), gender (women), not as determinants. Disease staging screening may improve identification high-risk patients.
Language: Английский
Citations
5
The Lancet Diabetes & Endocrinology, Journal Year: 2024, Volume and Issue: 12(10), P. 748 - 760
Published: July 22, 2024
Language: Английский
Citations
5